|
WO2021058656A1
|
|
Rifaximin liquid formulations
|
|
US2021087384A1
|
|
Grafted polymer and use thereof
|
|
WO2021048359A1
|
|
Methods of treating nonalcoholic fatty liver disease (nafld) using il-17ra antibody
|
|
US2021030778A1
|
|
Topical compositions
|
|
WO2020245214A1
|
|
Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
|
|
WO2020225395A1
|
|
Liquid oral dosage formulations of methylnaltrexone
|
|
WO2020191021A1
|
|
Topical compositions and methods for treating acne vulgaris
|
|
WO2020135990A1
|
|
Flexible circuit applicator for transcutaneous energy delivery
|
|
WO2020120274A1
|
|
Ceramic applicator for transcutaneous delivery of energy
|
|
TW202034856A
|
|
Microblade structure and method of treating tissue
|
|
US2020069955A1
|
|
Redundant traces for flexible circuits used in an energy delivery device
|
|
US2020069356A1
|
|
Pain mitigation by mechanical stimulation when treating tissue with electromagnetic energy
|
|
US2020069354A1
|
|
Methods and apparatus for pumping coolant to an energy delivery device
|
|
US2020074068A1
|
|
Encrypted memory device
|
|
US2019307682A1
|
|
Polymeric emulsion delivery systems
|
|
US2019307716A1
|
|
Topical pharmaceutical compositions for treating skin conditions
|
|
RU2738846C1
|
|
Methods of producing phenoxyethanol
|
|
AU2014331812A1
|
|
Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
|
|
AU2014235209A1
|
|
Guanylate cyclase receptor agonists combined with other drugs
|
|
AU2013232306A1
|
|
Formulations of guanylate cyclase C agonists and methods of use
|
